MACROBIOTICS IN INTEGRATIVE APPROACH TO TREATMENT AND SECONDARY PREVENTION OF VARIOUS MALIGNANCIES

MAKROBIOTIKA U INTEGRATIVNOM PRISTUPU LEČENJU I SEKUNDARNOJ PREVENCIJI KOD RAZNIH MALIGNIH OBOLJENJA

Nina Bulajic, M.D., Ph.D.VII Evropski kongres integrativne

medicine,Beograd, oktobar 2014.

Macrobiotics

Lifestyle based on ancient Chinese philosophyStaples: principles of the Universe based on YIN,

YANG & Five Energy Transformation theory Lifestyle: whole foods, maintenance of chi flow in

the body, personal developmentOriginates from Japan (G.Osawa, M.Kushi),

developed in XX century in Western countries, especially USA

Macrobiotics in integrative medicine

Weiger WA, Smith M, Boon H, Richardson MA, KaptchukTJ, Eisenberg DM. Advising Patients Who Seek Complementary and Alternative Medical Therapies for Cancer. Ann Intern Med, 2002, 137:889-903.

Lerman HR. The Macrobiotic Diet in Chronic Disease. Nutr Clin Pract 2010,25:621-626. : Carefully planned macrobiotic diet , as part of a healthy lifestyle, can be effective in the prevention of obesity, cardiovascular diseases, diabetes and cancer. It may also be a method of treatment in all these conditions.

The aim : Evaluation of macrobiotics in the treatment and secondary prevention of

cancer.

Cilj:Evaluacija makrobiotike u lečenju i

sekundarnojprevenciji kancera

Retrospective interventional studyRetrospektivna interventna studija

Inclusion criteria: 42 patients diagnosed with various malignancies who attended the macrobiotic consultations from 2006 – 2014

evaluated by conventional medicine with complete medical records

conducted advice on macrobiotic lifestyle at least 6 months

The macrobiotic diet was corrected in accordance with the latest scientific knowledge, when it was necessary, especially during chemotherapy protocols

Kriterijumi za uključenje u studiju: 42 pacijenta sa raznim malignitetima koji su došli na makrobiotičke konsultacije u periodu 2006-2014. i sa potpunom medicinskom dokumentacijom

Sprovodili makrobiotički stil života najmanje 6 meseci

Makrobiotička dijeta je korigovana u skladu sa najnovijim naučnim saznanjima kada je bilo potrebno, naročito za vreme hemioterapije

Age distribution (starosna distribucija)

Age at the reception No. of patients

25 - 30 230-40 540-50 650-60 2560-70 4

Gender distribution (rodna distribucija)

Total (ukupno): 42 patients

Female (ženski pol): 28 (66,6%)

Male (muškarci): 14 (33,4%)

Localisation of malignancy (lokalizacija maligniteta)

Primary localisation No. of patientsBreast (dojka) 9

Female genital organs (ženski genitalni organi)

6

Urinary bladder (mokraćna bešika) 1

Stomack and oesophagus (stomak i jednjak)

5

Colon (debelo crevo) 5

Liver (jetra) 2

Larynx (grkljan) 2

Lungs (pluća) 5

Haematological malignancies (hematološki maligniteti)

7

Invasiveness of malignancies (invazivnost maligne bolesti)

Invasiveness No.of patientsIn organ and regional lymph nodes (u organu i regionalnim limfnim žlezdama)

17

Spreading in local tissues and distant lymph nodes (širenje u lokalna tkiva i udaljene limfne žlezde)

11

Metastases in distant organs (metastaze u udaljenim organima)

8

Localised lymphomas (lokalizovani limfomi)

2

Diffuse lymphomas (difuzni limfomi) 2

Myeloma multiplex (multipli mijelom) 1

Policytemia (policitemija) 1

Oncological protocols (onkološki protokoli)

*Hepatocellular liver cancer; breast cancer - kancer jetre, kancer dojke

** Colon adenokarcinoma metastatic in lungs and liver; microcellular lung carcinoma metastatic in liver – kancer debelog creva sa metastazama na plućima i jetri, kancer pluća sa metastazama na jetri

***NHL (Non Hodžkin limfom) – after the first session of chemotherapy MB applied and no recidive for 3 years , Myeloma multiplex – bone marrow transplantation planned, MB applied, after 7 years no need for conventional medical treatment

Protocol CompletitionTotally completed (potpuno sproveden)

30 (71,4%)

Partly recejted (CT and /or radiotherapy) –delimično odbijen

6

Totally rejected (potpuno odbijen) 2 *

Lack of indications (bez indikacija) 2**

Unnecessary after adoption of macrobiotics (nepotreban nakon primene makrobiotike)

2***

MB intervention related to course of the diseaseVreme intervencije makrobiotikom

In the course of the disease(u toku bolesti)

32

After surgery without CT/ radiotherapy (posle operacije, bez dalje hemo ili radioterapije)

5

In remission of the disease(u remisiji)

1

Prevention after completed oncological protocol(prevencija nakon kompletno sprovedenog onkološkog protokola)

4

Favorable outcome of MB intervention – Uspešni ishodCourse of the disease Malignancy invasivennes Medical protocol No.of patients

Slowed progression(relatively favorable outcome) RELATIVNO USPEŠNI ISHOD

- In organs- In primary organ and

distant metastases- In organ- In primary organ and

distant metastases

- Complete- Complete

- No CT- No CT

55

12

Total 13

P rogression stoppedZAUSTAVLJENA PROGRESIJA

- NHL in remission- Myeloma multiplex- Breast cancer

metastatic in bones and lungs

00Hormonal treatment and chemical castration

111

Total 3

No relapse up to 5 yearsNo relapse 5 do 10 y

68

Favorable outcome (Uspešni ishod)

30 out of 42 patients (71,4%) – kod 30 od 42 pacijenta (71,4%) In 17 patients the progression of the disease completely halted or were

introduced into remission (56,6% favorable outcome), and in 13 cases the disease progression slowed after adoption of macrobiotics (according to oncological assessments in relation to the average of patients who do not carry out this lifestyle) – 43, 4% favorable outcome.

Kod 17 pacijenata progresija bolesti se potpuno zaustavila ili su uvedeni u remisiju (56,6% uspešnih ishoda), a u 13 slučajeva progresija bolesti se usporila (prema onkološkoj proceni u odnosu na prosečne pacijente koji nisu usvojili ovaj način života) – 43,4% uspešnog ishoda

Patients without relapse up to 5 years (No. 6)Pacijenti bez pojave bolesti do 5 godina

Patient Malignancy Med. therapy Start of MB No relapse up to

V.V. NHLNon Hodžkin limfom

Complete At the end of protocol

1,5 y

S.D. NHL Complete At the beginning of protocol

5 y

D.Z. NHL Complete until remission

In remission 3 y

S.V. Urinary bladderMokraćna bešika

Complete U the course of protocol

2 y

M.D. GastricŽeludac

Complete After protocol 3,5 y

A.S. OvarialJajnik

Only surgery After surgery 2 y

Patients without relapse more than 5 years (No. 8) Pacijenti bez pojave bolesti više od 5 godina

Patient Malignancy Med. therapy Start of MB No relapse up to

M.Đ. Cervix – Grlić materice

Complete After protocol 8 y

J.B. Colon- Debelo crevo

Surgery After surgery 8 y

N.A. Larynx- Grkljan Complete After protocol 5,5 y

B.V. Lungs - Pluća Complete (surgery)

After protocol 10 y, 6 on MB

S.K. Breast - Dojka Complete At the beginning of protocol

8 y

M.LJ: Uterus - Materica Complete At the end of protocol

8 y

G.C. Policytemia Complete During protocol 7 y

J.K. Myeloma multiplex

Unnecessary Before medical treatment , 1 y after diagnosis

7 y

Unfavorable outcome after MB intervention12 out of 42 (28,6%)Nepovoljni ishod nakon primene makrobiotike – 12 od 42 pacijenta (28,6%)

Course of disease Invasiveness of malignancy

Medical protocol No of patients

No effectBez efekta

- In organ- In prim organ and

distant metastases- In organ

- Complete- Complete

- No CT

2 (lungs, ovarial3 (lungs, colon, HL)2 (breast)

Total 7

Progression in other organsProgresija u druge organe

1. Breast cancer

2. Stomack cancer

3. Larynx cancer

After CT metastases in liverAfter CT metastases in liverAfter CT metastases in lungs

1

1

1

Total 3

RelapsesPonovna pojava bolesti

1. Breast cancer

2. Colon cancer

-CT rejected after surgery, MB applied, local recidive

- After surgery, CT i MB, remission, after new ovarial cancer, CT repeated

1

1

The course of the disease related to degree of oncological protocol rejectionTok bolesti u odnosu na odbijanje onkološkog protokola

Patient Malignancy Med. intervention

Outcome

J.B. Colon cancer Surgery No relapse up to 8 y

A.S. Breast cancer Surgery No relapse up to 2 y

Z.I. Breast cancer CT, ceasses for negative side effects

MB with no effect, lethal outcome

M.K. Breast cancer Surgery No relapse up to 2 y, later unknown

LJ.N. Breast cancer Surgery, CT rejected

MB with no effect, lethal o.

J.Š. Breast cancer Surgery, CT rejected

Loc. relapse, afterwards completed protocole

The course of the disease related to degree of oncological protocol rejectionTok bolesti u odnosu na stepen odbijanja onkološkog protokola

8 patients had not implemented the proposed oncology protocol. In 2 cases of complete and 2 cases of partial rejection the outcome was lethal, in one case of partial rejection there was a relapse, and in 3 cases of partial rejection of the protocol relapse did not appear over 2 years.

8 pacijenata nisu prihvatili preporučeni onkološki protokol. U 2 slučaja potpunog i 2 slučaja delimičnog odbijanja ishod je bio fatalan, u jednom slučaju delimičnog odbijanja bolest se ponovo javila, a u 3 slučaja delimičnog odbijanja protokola bolest se nije javila više od 2 godine

ConclusionZaključakMacrobiotics is a valuable method of

traditional medicine in the secondary prevention of malignancies, and also can be effectively used as a complementary method in the treatment of cancer.

Makrobiotika je vredna metoda tradicionalne medicine u sekundarnoj prevenciji malignih bolesti, a takođe i efikasna komplementarna metoda u lečenju kancera.